# Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

Source: https://onco.cc/trials/nct04446117/  
OnCo record `nct04446117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cabozantinib, Atezolizumab, Abiraterone acetate in prostate cancer, run by Exelixis, active and no longer recruiting.

## Summary

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC is a phase 3 interventional study registered as NCT04446117 by Exelixis, with 575 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2024-04-19. Interventions recorded: Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide, Prednisone. Conditions listed: Metastatic Prostate Cancer, Prostate Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04446117
- Phase: 3
- Setting: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Exelixis
- Enrolled: 575

## Sources

- ClinicalTrials.gov NCT04446117: https://clinicaltrials.gov/study/NCT04446117

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct04446117.json